Attention javascript est désactivé sur votre poste.
Ce site nécessite l'activation de javascript pour fonctionner correctement.
Also learn about Oncodesign Services, dedicated to CRO activities in Drug Discovery
Learn more
Also learn about Oncodesign Services, dedicated to CRO activities in Drug Discovery
Learn more
Our pipeline
Partnering
Our innovation technologies
OncoSNIPER
Nanocyclix
PROMETHE
Investors
Message from the chairman
Regulated information [FR]
Press Release
General Meetings [FR]
About us
Latest news
Our history
Management
Our HR policy
Our CSR approach
FederAidd
Contact us
Regulated information [FR]
All documents
Communiqué de presse
Actualité
All dates
2022
2023
01/07/2022
OPM – Attestation de valeur
Lire la suite
01/07/2022
[CP] Oncodesign annonce la séparation de ses deux branches d’activité Service et Biotech
Lire le communiqué
1
2
3
4
